Revelation Biosciences
REVB
12 hedge funds and large institutions have $241K invested in Revelation Biosciences in 2026 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
9% more funds holding
Funds holding: 11 → 12 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.4% less ownership
Funds ownership: 7.79% → 7.38% (-0.4%)
10% less capital inflows, than outflows
Capital inflows: $95.6K | Capital outflows: $106K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$62.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$13.6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$108 |
| 5 |
Citigroup
New York
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$85.8K |
| 2 |
HRT Financial
New York
|
-$17K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$2.72K |
| 4 |
Barclays
London,
United Kingdom
|
-$173 |
REVB Hedge Fund Activity: Q3 2026 in Review
12 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q3 2026, worth a combined $241K — down 23% from $313K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new REVB positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $62.4K. The largest seller was Sabby Management, cutting an estimated $85.8K.
- 12 institutional investors held Revelation Biosciences (REVB) as of Q3 2026, up from 11 in Q2 2026.
- Funds reported $241K of Revelation Biosciences stock for Q3 2026, down 23% quarter-over-quarter.
- 3 funds opened new Revelation Biosciences positions in Q3 2026 and 2 closed out, a net change of +1 holder.
- The largest Revelation Biosciences buyer in Q3 2026 was Citadel Advisors, an estimated $62.4K added.
- The largest Revelation Biosciences seller in Q3 2026 was Sabby Management, an estimated $85.8K sold.
Based on aggregated 13F filings for Q3 2026.